Cambrex Invests in New Continuous Flow Technology at US Facility

Cambrex Corporation, US-based manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has completed the installation of multiple continuous flow reactor platforms at its High Point, North Carolina (US) facility. “This latest investment in continuous flow for process development will focus on the rapid and successful development of processes to supply clinical as well as commercial demand for chemical syntheses,” the company said. The investment in developmental capabilities builds upon the recent expansions made at the commercial-scale in the dedicated continuous flow production unit, at the Karlskoga, Sweden facility, which is capable of producing multiple metric tons of high purity intermediates per annum.

“We are seeing significant interest in continuous flow development and production, predominantly from established pharmaceutical companies looking for process improvements in Phase II,” commented Mr. Brian Swierenga, VP, Operations and Site Director for Cambrex High Point “We have designed the new laboratory and GMP pilot plant with maximum flexibility in mind, allowing us to explore the possibilities for both new and existing production projects, either on a FTE or custom contract basis,” he added. The continuous flow development centre is the latest investment at Cambrex’s High Point site which has recently seen the completion and qualification of a new 11,000 sq.ft. analytical laboratory and a 400 sq.ft. pilot plant expansion with a reactor capacity of 4,000 litres.